[go: up one dir, main page]

AR098414A1 - PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e - Google Patents

PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Info

Publication number
AR098414A1
AR098414A1 ARP140104277A ARP140104277A AR098414A1 AR 098414 A1 AR098414 A1 AR 098414A1 AR P140104277 A ARP140104277 A AR P140104277A AR P140104277 A ARP140104277 A AR P140104277A AR 098414 A1 AR098414 A1 AR 098414A1
Authority
AR
Argentina
Prior art keywords
substituted
independently selected
nrara
heterocyclyl
alkyl
Prior art date
Application number
ARP140104277A
Other languages
English (en)
Inventor
Velaparthi Upender
Padmakar Darne Chetan
Liu Peiying
D Wittman Mark
C Pearce Bradley
Araujo Erika
Dasgupta Bireshwar
Surendran Nair Jalathi
Kumaran Janakiraman Sakthi
Reddy Rachamreddy Chandrasekhar
Mallikarjuna Rao Mettu
Mozhi Selvan Subbiah Karuppiah Arul
Subba Reddy Bandreddy
Nagalakshmi Pulicharla
Onkardas Bora Rajesh
Holehatti Maheshwarappa Shilpa
Selvakumar Kumaravel
Mullick Dibakar
Sistla Ramesh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR098414A1 publication Critical patent/AR098414A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Sales de aquellos aceptables desde el punto de vista farmacéutico. Los compuestos inhiben la actividad de la proteína quinasa, lo cual los vuelve útiles como agentes antineoplásicos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde X se selecciona independientemente de O y NH; R¹ se selecciona independientemente de carbociclilo sustituido con 1 - 5 R⁵, y heterociclilo que comprende átomos de carbono y 1 a 3 heteroátomos seleccionados de N, NR⁴, O, S, y sustituidos con 1 - 5 R⁵; R² se selecciona independientemente de (i) alquilo opcionalmente sustituido con F, Cl, Br, ORᵇ, CN, NRᵃRᵃ, -C(=O)NRᵃRᵃ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, carbociclilo sustituido con 1 - 8 R⁷ y heterociclilo que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, NR⁶, O, S, y sustituidos con 1 - 8 R⁷, (ii) cicloalquilo sustituido con 1 - 8 R⁷, y (iii) cicloheteroalquilo sustituido con 1 - 8 R⁷; R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ y R³ᶠ se seleccionan independientemente de H, CN, C₁₋₄ alquilo sustituido con 1 - 3 R⁸, -C(=O)ORᵇ, -C(=O)NRᵃRᵃ, -C(=O)Rᵇ, -NRᵃC(=O)Rᵇ, -NRᵃC(=O)ORᵇ, -(CH₂)ʳ-carbociclilo sustituido con 1 - 3 R⁸ y -(CH₂)ʳ-heterociclilo sustituido con 1 - 3 R⁸; de manera alternativa, R³ᵃ y R³ᵇ, o R³ᶜ y R³ᵈ o R³ᵉ y R³ᶠ, junto con el átomo de carbono al que están unidos, forman un anillo spiro carbocíclico o heterocíclico que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, O, S, cada uno sustituido con 1 - 5 R⁸; de manera alternativa, R³ᵃ y R³ᶜ, o R³ᵇ y R³ᵈ, juntos forman un anillo heterocíclico que comprende átomos de carbono y 1 a 4 heteroátomos seleccionados de N, O, S, y sustituidos con 1 - 5 R⁸; R⁴ se selecciona independientemente de H, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ʳCN, -(CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, -(CH₂)ʳC(=O)Rᵇ, -(CH₂)ʳNRᵃRᵃ, -(CH₂)ʳC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)Rᵇ, -(CH₂)ʳNRᵃC(=O)ORᵇ, -(CH₂)ʳOC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)NRᵃRᵃ, -(CH₂)ʳC(=O)ORᵇ, -(CH₂)ʳS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂Rᶜ, (CH₂)ʳ-carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 3 Rᵉ; R⁵, en cada caso, se selecciona independientemente de H, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, F, Cl, Br, =O, CN, NO₂, -ORᵇ, -(CH₂)ʳCN, -(CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, -(CH₂)ʳC(=O)Rᵇ, -(CH₂)ʳNRᵃRᵃ, -(CH₂)ʳC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)Rᵇ, -(CH₂)ʳNRᵃC(=O)ORᵇ, -(CH₂)ʳOC(=O)NRᵃRᵃ, -(CH₂)ʳNRᵃC(=O)NRᵃRᵃ, -(CH₂)ʳC(=O)ORᵇ, -(CH₂)ʳS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂NRᵃRᵃ, -(CH₂)ʳNRᵃS(O)₂Rᶜ, (CH₂)ʳ-carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 3 Rᵉ; R⁶ se selecciona independientemente de H, -C(=O)Rᵇ, -CO(=O)Rᵇ, -S(O)ₚRᶜ, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ; -(CH₂)ʳ-C₃₋₆ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; R⁷, en cada caso, se selecciona independientemente de H, F, Cl, Br, =O, -(CRᵈRᵈ)ʳCN, NO₂, -(CRᵈRᵈ)ʳORᵇ, -S(O)ₚRᶜ, -C(=O)Rᵇ, -(CRᵈRᵈ)ʳNRᵃRᵃ, -(CRᵈRᵈ)ʳC(=O)NRᵃRᵃ, -NRᵃ(=O)Rᵇ, -NRᵃC(=O)ORᵇ, -OC(=O)NRᵃRᵃ, -NRᵃC(=O)NRᵃRᵃ, -(CRᵈRᵈ)ʳC(=O)ORᵇ, -S(O)₂NRᵃRᵃ, -NRᵃS(O)₂NRᵃRᵃ, -NRᵃS(O)₂Rᶜ, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, -(CRᵈRᵈ)ʳ-C₃₋₆ carbociclilo sustituido con 0 - 5 Rᵉ y -(CRᵈRᵈ)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; R⁸, en cada caso, se selecciona independientemente de H, F, Cl, Br, CN, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ʳ-C₃₋₆ cicloalquilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-arilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ, CO₂H, -(CH₂)ʳORᵇ y -(CH₂)ʳNRᵃRᵃ; Rᵃ, en cada caso, se selecciona independientemente de H, CN, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ʳ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ʳ-heterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente de C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₄ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente de F, Cl, Br, CN, NO₂, =O, C₁₋₆ alquilo sustituido con 0 - 5 Rᶠ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -(CH₂)ʳ-C₃₋₆ cicloalquilo, -(CH₂)ʳ-arilo, -(CH₂)ʳ-heterociclilo, CO₂H, -(CH₂)ʳORᶠ, SRᶠ, y -(CH₂)ʳNRᶠRᶠ; Rᶠ, en cada caso, se selecciona independientemente de H, C₁₋₅ alquilo, opcionalmente sustituido con F, Cl, Br, C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; p, en cada caso, se selecciona independientemente de 0, 1 y 2; y r, en cada caso, se selecciona independientemente de 0, 1, 2, 3 y 4.
ARP140104277A 2013-11-14 2014-11-13 PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e AR098414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
AR098414A1 true AR098414A1 (es) 2016-05-26

Family

ID=51952052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104277A AR098414A1 (es) 2013-11-14 2014-11-13 PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Country Status (9)

Country Link
US (3) US9598423B2 (es)
EP (2) EP3068784B1 (es)
JP (2) JP6494624B2 (es)
CN (2) CN105916855B (es)
AR (1) AR098414A1 (es)
ES (2) ES2744636T3 (es)
TW (1) TW201605859A (es)
UY (1) UY35834A (es)
WO (2) WO2015073763A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
EP3112369A4 (en) * 2014-02-27 2017-09-20 The University of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2017198744A1 (en) * 2016-05-20 2017-11-23 F. Hoffmann-La Roche Ag Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
CA3038331A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
CN109952305B (zh) * 2017-07-27 2022-06-21 江苏恒瑞医药股份有限公司 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
BR112020008457A2 (pt) 2017-11-01 2020-10-20 Bristol-Myers Squibb Company compostos bicíclicos em ponte como moduladores de receptor de farnesoide x
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) * 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN111484442B (zh) * 2018-06-01 2021-11-09 杭州阿诺生物医药科技有限公司 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
AR116474A1 (es) 2018-09-21 2021-05-12 Enanta Pharm Inc DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
MX2021008929A (es) * 2019-01-25 2021-08-24 Jiangsu Hengrui Medicine Co Forma cristalina de un derivado de 1,2,3-triazolo[1,5-a]pirazinas, y metodo de preparacion para la forma de cristal.
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
MX2023003165A (es) * 2020-09-17 2023-06-07 Janssen Pharmaceutica Nv Moduladores de la caseína cinasa 1 delta.
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
TW202245772A (zh) * 2021-02-04 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法
EP4469457A1 (en) * 2022-01-27 2024-12-04 The Broad Institute Inc. Substituted heterocyclic csnk1 inhibitors
CN119365463A (zh) * 2022-06-13 2025-01-24 盐野义制药株式会社 二氢吡啶酮衍生物或其溶剂合物的晶体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391958C (zh) * 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
DE602004020685D1 (de) * 2003-12-11 2009-05-28 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2346335B1 (en) 2008-09-24 2018-11-14 Basf Se Pyrazole compounds for controlling invertebrate pests
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Also Published As

Publication number Publication date
JP6494622B2 (ja) 2019-04-03
EP3068784B1 (en) 2019-02-20
US20160122358A1 (en) 2016-05-05
JP6494624B2 (ja) 2019-04-03
ES2718218T3 (es) 2019-06-28
EP3068784A1 (en) 2016-09-21
CN105916855B (zh) 2019-03-15
CN105916856B (zh) 2018-09-25
US20160311824A1 (en) 2016-10-27
JP2016537369A (ja) 2016-12-01
ES2744636T3 (es) 2020-02-25
UY35834A (es) 2015-05-29
US9598423B2 (en) 2017-03-21
JP2016537366A (ja) 2016-12-01
WO2015073763A1 (en) 2015-05-21
CN105916856A (zh) 2016-08-31
EP3068785A1 (en) 2016-09-21
TW201605859A (zh) 2016-02-16
EP3068785B1 (en) 2019-06-26
CN105916855A (zh) 2016-08-31
US9273058B2 (en) 2016-03-01
US20150133428A1 (en) 2015-05-14
WO2015073767A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR096450A1 (es) Compuestos para la modulación de quinasas, y sus indicaciones
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR110405A1 (es) Compuestos
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR111419A1 (es) Compuestos fusionados de indazol piridona como antivirales
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097866A1 (es) Derivados de 4-azaindol
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR093758A1 (es) Inhibidores de aril lactama quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure